AMAG Pharmaceuticals (NASDAQ:AMAG) Rating Lowered to Sell at BidaskClub

BidaskClub cut shares of AMAG Pharmaceuticals (NASDAQ:AMAG) from a hold rating to a sell rating in a research note released on Thursday morning, BidAskClub reports.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Several other equities analysts also recently commented on AMAG. ValuEngine downgraded AMAG Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Thursday, October 31st. Barclays reaffirmed a buy rating and issued a $14.00 target price (down previously from $16.00) on shares of AMAG Pharmaceuticals in a research report on Sunday, November 3rd. Needham & Company LLC reaffirmed a hold rating on shares of AMAG Pharmaceuticals in a research report on Friday, October 25th. HC Wainwright reaffirmed a buy rating and issued a $16.00 target price on shares of AMAG Pharmaceuticals in a research report on Thursday, August 8th. Finally, Piper Jaffray Companies downgraded AMAG Pharmaceuticals from a neutral rating to an underweight rating and decreased their target price for the company from $9.00 to $6.00 in a research report on Wednesday, October 30th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of Hold and a consensus price target of $13.28.

Shares of AMAG Pharmaceuticals stock traded up $0.32 during trading on Thursday, reaching $9.38. The stock had a trading volume of 613,200 shares, compared to its average volume of 909,994. The stock has a fifty day moving average price of $11.37 and a two-hundred day moving average price of $10.50. The company has a market capitalization of $315.36 million, a price-to-earnings ratio of -2.42 and a beta of 0.35. The company has a current ratio of 1.67, a quick ratio of 1.53 and a debt-to-equity ratio of 0.58. AMAG Pharmaceuticals has a 52 week low of $6.81 and a 52 week high of $19.44.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings results on Friday, November 1st. The specialty pharmaceutical company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.19). The business had revenue of $84.13 million for the quarter, compared to analyst estimates of $88.25 million. AMAG Pharmaceuticals had a negative return on equity of 34.59% and a negative net margin of 88.54%. AMAG Pharmaceuticals’s quarterly revenue was down 31.2% compared to the same quarter last year. During the same period last year, the firm earned $0.89 EPS. On average, equities analysts forecast that AMAG Pharmaceuticals will post -2.64 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of AMAG. Nuveen Asset Management LLC acquired a new position in shares of AMAG Pharmaceuticals in the second quarter valued at approximately $6,911,000. Camber Capital Management LP grew its position in AMAG Pharmaceuticals by 13.2% during the second quarter. Camber Capital Management LP now owns 3,000,000 shares of the specialty pharmaceutical company’s stock worth $29,970,000 after buying an additional 350,000 shares in the last quarter. Acadian Asset Management LLC grew its position in AMAG Pharmaceuticals by 34.7% during the second quarter. Acadian Asset Management LLC now owns 919,064 shares of the specialty pharmaceutical company’s stock worth $9,180,000 after buying an additional 236,984 shares in the last quarter. Permanens Capital L.P. grew its position in AMAG Pharmaceuticals by 319.7% during the second quarter. Permanens Capital L.P. now owns 266,500 shares of the specialty pharmaceutical company’s stock worth $2,662,000 after buying an additional 203,000 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its position in AMAG Pharmaceuticals by 66.8% during the second quarter. Jacobs Levy Equity Management Inc. now owns 447,715 shares of the specialty pharmaceutical company’s stock worth $4,473,000 after buying an additional 179,310 shares in the last quarter.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Read More: How dollar cost averaging works

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Leave a Reply

Your email address will not be published. Required fields are marked *

*